Falling under the broad category of women’s health, prenatal testing seeks to detect whether a baby is at risk for a variety of genetic conditions. With 3.5 million reproductive genetic tests expected to be performed annually in the U.S. by 2023, these two prenatal testing stocks could offer investors a way to capitalize on this trend. CLICK HERE.
Assessing Prenatal Testing Stocks
- by Ashley Hayes